Martina Schell

Title: Martina Schell: Innovator in Oncolytic Virus Research

Introduction

Martina Schell is a prominent inventor based in Tuebingen, Germany. She has made significant contributions to the field of pharmaceutical compositions, particularly in the development of oncolytic viruses for cancer treatment. Her innovative work focuses on utilizing recombinant measles viruses to target malignant cells effectively.

Latest Patents

Martina Schell holds a patent for her invention related to an oncolytic measles virus. The patent describes a pharmaceutical composition that includes a recombinant measles virus encoding a suicide gene. This composition is designed for the treatment of malignant cells that exhibit primary or secondary resistance against an oncolytic measles virus without suicide gene activity. The invention also details a recombinant measles virus based on the measles vaccine strain Schwarz, which encodes a suicide gene. This gene comprises a fusion of cytosine deaminase and uracil phosphoribosyltransferase, specifically from yeast, and includes methods and kits for preparing the recombinant measles virus.

Career Highlights

Throughout her career, Martina has demonstrated a strong commitment to advancing medical research and innovation. Her work has the potential to revolutionize cancer treatment by providing new therapeutic options for patients with resistant forms of cancer.

Collaborations

Martina Schell has collaborated with notable colleagues, including Ulrich Manfred Lauer and Michael Bitzer. These partnerships have contributed to the development and refinement of her innovative research.

Conclusion

Martina Schell is a trailblazer in the field of oncolytic virus research, with her patented inventions paving the way for new cancer therapies. Her dedication to innovation and collaboration highlights the importance of teamwork in scientific advancements.